KYMERA THERAPEUTICS
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
KYMERA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kymeratx.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
604 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
Abata Therapeutics
Abata Therapeutics is a biotech company.
Allay Therapeutics
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Casma Therapeutics
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Freeline
Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Mahana Therapeutics
Mahana Therapeutics is a developer of digital treatments for people living with gastrointestinal conditions.
Neogene Therapeutics
Neogene Therapeutics is a biotech company providing cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Seer
Seer is a biotechnology company that offers tools and solutions related to the field of proteomics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Kymera Therapeutics
Redmile Group
Redmile Group investment in Post-IPO Equity - Kymera Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Kymera Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Post-IPO Equity - Kymera Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Post-IPO Equity - Kymera Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Kymera Therapeutics
Solasta Ventures
Solasta Ventures investment in Series C - Kymera Therapeutics
Redmile Group
Redmile Group investment in Series C - Kymera Therapeutics
BlackRock
BlackRock investment in Series C - Kymera Therapeutics
Bessemer Venture Partners
Bessemer Venture Partners investment in Series C - Kymera Therapeutics
Key Employee Changes
Official Site Inspections
http://www.kymeratx.com Semrush global rank: 1.88 M Semrush visits lastest month: 11.68 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kymera Therapeutics"
Our Company - Kymera Therapeutics
Mar 31, 2023 Leading the Charge for Transformative Therapeutics . Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines …See details»
About Us - Kymera Therapeutics
500 North Beacon Street, 4th Floor, Watertown, MA 02472 © 2024 Kymera Therapeutics. All Rights Reserved.See details»
Kymera Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It …See details»
Kymera Therapeutics - LinkedIn
Kymera Therapeutics | 31,047 followers on LinkedIn. Inventing a new class of medicines using Targeted Protein Degradation | Kymera is a clinical-stage biotechnology company pioneering the field of ...See details»
Kymera Therapeutics - Overview, News & Similar companies
Jun 1, 2024 Kymera Therapeutics contact info: Phone number: (857) 285-5300 Website: www.kymeratx.com What does Kymera Therapeutics do? Kymera Therapeutics (Nasdaq: …See details»
Kymera Overview | Kymera Therapeutics, Inc.
Nov 18, 2024 Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing …See details»
Kymera Therapeutics Announces Key 2022 Goals and Milestones
Jan 10, 2022 Scale organization with continued growth in key functional areas, including clinical development, manufacturing, drug discovery, preclinical development, and G&A functions to …See details»
Release Details - Kymera Therapeutics, Inc.
Dec 6, 2021 “He has a demonstrated history of building and growing high-performing teams and developing leaders within the organization, which will be vital for Kymera as we advance our …See details»
Kymera Therapeutics Strengthens Leadership Team with the …
WATERTOWN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein …See details»
Working at Kymera - Kymera Therapeutics
Our Clinical Development group has played a major role transforming the company from a research organization into one with multiple programs in the clinic. With a newer modality, the bar is high, and Kymera’s team has created …See details»
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein …See details»
Kymera Therapeutics Announces Third Quarter 2020 Financial …
Nov 5, 2020 Expanded organization with the addition of Chief Scientific Officer and two new appointees to the Board of Directors. ... [email protected] Bruce Jacobs Chief …See details»
Kymera Therapeutics Appoints Healthcare Industry Leader John …
WATERTOWN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein …See details»
Careers & Culture - Kymera Therapeutics
Working at Kymera . Our shared values and a deep commitment to improving patients’ lives are the guiding principles that drive our work and connect our diverse and experienced teams to …See details»
Release Details - Kymera Therapeutics, Inc.
Aug 3, 2023 [email protected] 857-285-5300 Justine Koenigsberg Vice President, Investor Relations [email protected] 857-285-5300: Media Contact: Todd Cooper …See details»
Release Details - investors.kymeratx.com
Aug 9, 2022 To access the conference call via phone, please dial 877-317-6789 (U.S.) or +1 412-317-6789 (International) and ask to join the Kymera Therapeutics call. A live webcast of …See details»
Kymera Therapeutics Announces First Quarter 2023 Financial …
Mar 31, 2023 To access the conference call via phone, please dial +1 (833) 630-2127 (U.S.) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast …See details»
Kymera Therapeutics Announces Fourth Quarter and Full Year …
Mar 11, 2021 [email protected] 917-754-0207. Media: Lissette L. Steele Verge Scientific Communications for Kymera Therapeutics [email protected] 202-930-4762. …See details»
Pipeline - Kymera Therapeutics
Kymera’s pipeline is focused on addressing disease targets where there is significant patient need and where we believe protein degradation is the only or best way to improve the standard of care.See details»